utrition the Unrecognized Determinant for Alzheimer's Disease (NUDAD-L)
- Conditions
- Alzheimer's diseasedementia10012272
- Registration Number
- NL-OMON46227
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Label of either subjective cognitive decline, Mild Cognitive Impairment or Alzheimer's Disease Signed informed consent projects P2005_160, P2000_211 (SCD: also SCIENCe P2014-019)
Age * 50 years
MMSE*19
Individuals who are considered medically unstable (assessed by physician)
Insufficient knowledge of Dutch language
Major psychiatric disorder, such as psychosis, schizophrenia, severe personality disorder or depression with vital signs, abuse of alcohol or other substances
Neurological disorder such as Parkinson*s disease, symptomatic stroke, mental retardation
Having a history of other neurological disorders known to influence smell and/or taste
Acquired Immune Deficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV)
Having a severe food allergy
Having a severe disease of the digestive tract, such as celiac disease, Crohn*s disease, active ulcerative colitis, short bowel syndrome
Having a severe metabolic disorder, such as phenyl ketonuria
A recent diagnosis of cancer or being actively treated for cancer (excluding basal cell carcinoma of the skin)
Having a current upper respiratory infection or severe COPD (known GOLD 3 or 4)
Being a regular smoker
In MCI and AD patients: unavailability of a study partner to assist with the participation of NUDAD-L in patients with dementia
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Nutritional intake in patients with AD, in comparison with subjects with<br /><br>subjective cognitive decline or MCI.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Determining changed energy needs and body composition in patients with<br /><br>(pre-dementia) AD compared to healthy people and patients with advanced AD.<br /><br>Identifing altered eating behaviour in terms of olfactory and gustatory<br /><br>functioning, food preferences and satiety as determinants of altered food<br /><br>intake in patients with (pre-dementia) AD compared to healthy people and<br /><br>patients with advanced AD.<br /><br>Establishing relationships between nutritional intake and energy needs & body<br /><br>composition, and nutritional biomarkers.<br /><br>Pospectively validating panel of nutritional markers and relate them to<br /><br>measures of nutritional intake, energy requirements and body composition.<br /><br>Relating these markers to in*vivo measures of AD pathology (i.e. MRI, CSF<br /><br>biomarkers for AD, APOE status, EEG).</p><br>